Q&A with Xiyin Wang: Targeting a Shared Vulnerability in Breast and Ovarian Cancer

Triple-negative breast cancer and ovarian cancer remain among the most lethal cancers in women, largely due to a lack of effective therapeutic options.

Xiyin Wang, MS, a graduate student at Mayo Clinic, received a 2024 PhRMA Foundation Predoctoral Fellowship in Drug Discovery for his research on a common molecular feature essential for the survival of both cancers. He is now investigating a potential drug candidate that targets this shared cellular vulnerability.

Watch this video to learn about Wang and his research.

Learn more about the PhRMA Foundation’s fellowship and grant opportunities. Check out more researcher stories on our blog.